Hydrothermally modified slow release corn starch: a potential new therapeutic option for treating hypoglycemia in autoimmune hypoglycemia (Hirata's disease)

Eur J Clin Nutr. 2015 Dec;69(12):1369-70. doi: 10.1038/ejcn.2015.151. Epub 2015 Sep 16.

Abstract

We report the successful treatment of autoimmune hypoglycemia in an 82-year-old non-diabetic Caucasian male with hydrothermally modified slow release corn starch, a product which is used in other conditions associated with hypoglycemia, most typically glycogen storage disease type I. An 82-year-old-Caucasian male presented with recurrent spontaneous hypoglycemia as low as 30 mg/dl following in-patient treatment for community acquired pneumonia. During a fasting-test, symptomatic hypoglycemia occurred. Plasma concentrations of c-peptide and insulin were considerably elevated. Autoimmune hypoglycemia was confirmed by the presence of insulin autoantibodies. While dietary restriction alone did not result in sufficient glucose control in this patient with autoimmune hypoglycemia, treatment with hydrothermally modified slow release corn starch led to stable euglycemia. This easy, well tolerated and non-invasive treatment may constitute a new therapeutic option for hypoglycemia in patients with autoimmune hypoglycemia who do not achieve sufficient control of hypoglycemia by dietary restriction alone.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • C-Peptide / blood
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / therapeutic use*
  • Glycogen Storage Disease Type I / blood
  • Glycogen Storage Disease Type I / diagnosis
  • Glycogen Storage Disease Type I / diet therapy
  • Humans
  • Hypoglycemia / blood
  • Hypoglycemia / diagnosis
  • Hypoglycemia / diet therapy*
  • Insulin / blood
  • Insulin Antibodies / blood
  • Male
  • Starch / chemistry
  • Starch / therapeutic use*
  • Zea mays / chemistry*

Substances

  • C-Peptide
  • Delayed-Action Preparations
  • Insulin
  • Insulin Antibodies
  • Starch